- Last sale
- Sep 18, 2026 · +11.36%
- Market cap
- $76.41M
- 13.92M shares
- Filings
- 659
Q1 2027+4.4% FY26 yoy
Q1 2027N/M FY26 yoy
Q1 2027N/M FY26 yoy
Q1 2027derivedN/M FY26 yoy
FY 2026N/M FY26 yoy
Q1 2027−50.2% FY26 yoy
- $76.41M
- —
- 1.3×
- 19.6×
- -8.03%
- —
Twelve months to Jul 31, 2026 · derived
Price
Sep 18, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2026 | 2026-04-30 | $59,425,000 | reported | |
| FY 2025 | 2025-04-30 | $56,944,000 | reported | |
| FY 2024 | 2024-04-30 | $50,155,000 | reported | |
| FY 2023 | 2023-04-30 | $53,870,000 | reported | |
| FY 2022 | 2022-04-30 | $49,109,000 | reported | |
| FY 2021 | 2021-04-30 | $41,040,000 | reported | |
| FY 2020 | 2020-04-30 | $32,123,000 | reported | |
| FY 2019 | 2019-04-30 | $27,067,000 | reported | |
| FY 2018 | 2018-04-30 | $20,241,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $0.00 | $0.00 | — | 13.78M sh | +1.3% | 0.0% |
| FY2024 | — | $634.00K | $634.00K | — | 13.59M sh | +1.0% | — |
| FY2023 | — | $74.00K | $74.00K | — | 13.46M sh | −0.5% | 6.7% |
| FY2022 | — | $0.00 | $0.00 | — | 13.52M sh | +0.8% | 0.0% |
| FY2012 | — | $0.00 | $0.00 | — | 47.07M sh | +39.0% | — |
Segments
Products
LineFY2026ShareChange
Pharmacology services$57.13M96%+17.6%
Other TOS revenue$1.53M2.6%−58.5%
TOS data license revenue$764.00K1.3%−83.7%
Other TOS revenue———
Personalized oncology services———
TOS data license revenue———
Total$59.43M
Champions Oncology, Inc. · CIK 771856 · Engraved from SEC EDGAR